Table 1.

A summary of reports on furfuryl palmitate and its derivatives (Pigatto and Diani, 2018).

Lead author; year	Agent	Study design; number of patients	Results; adverse events	Formulation; duration of treatment; frequency of applications
Patrizi et al., 2012	Sorbityl furfural palmitate vs. placebo	Single-center, double-blinded, randomized, placebo-controlled study; 60 pediatric patients	Significant reduction of itching and severity; no severe adverse events	Cream; 30 days; twice a day
Nemelka et al., 2002	Superoxide dismutase, 18 beta-glycyrrhetinic acid, vitamin E, alpha bisabolol, and furfuryl palmitate	Unilateral trial; 60 pediatric patients	Improvement of inflammatory skin conditions; no relevant adverse events	Cream; 2 weeks; twice a day
Bocchietto et al., 2002	Superoxide dismutase, 18 beta-glycyrrhetinic acid, vitamin E, alpha bisabolol, and furfuryl palmitate	Unilateral trial; 64 adults and 44 pediatric patients	Reduction of erythema and itching; no relevant adverse events	Cream; 2 weeks; twice a day
Pigatto et al., 2011	Furpalmate vs. vehicle	Double-blinded, randomized, placebo-controlled study; 40 adult patients	Reduction of signs and symptoms of atopic dermatitis; no severe adverse events	Cream; 21 days; twice a day
Lauriola et al., 2011	Furpalmate vs. topical corticosteroid	Investigator-blinded, randomized, placebo-controlled study; 40 adult patients	Both groups significantly improved from baseline with no difference between the groups	Cream; 14 days; twice a day
Tripodi et al., 2009	Emollient cream enriched with furfuryl palmitate vs. emollient cream	Randomized controlled trial; 117 pediatric patients	No statistical difference, but treatment product was less tolerated	Cream; 14 days; twice a day